首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   18318篇
  免费   1597篇
  国内免费   43篇
耳鼻咽喉   125篇
儿科学   462篇
妇产科学   408篇
基础医学   2593篇
口腔科学   305篇
临床医学   1708篇
内科学   3794篇
皮肤病学   295篇
神经病学   1476篇
特种医学   669篇
外国民族医学   4篇
外科学   2383篇
综合类   184篇
一般理论   4篇
预防医学   3060篇
眼科学   267篇
药学   949篇
中国医学   8篇
肿瘤学   1264篇
  2022年   125篇
  2021年   216篇
  2020年   201篇
  2019年   239篇
  2018年   349篇
  2017年   269篇
  2016年   273篇
  2015年   333篇
  2014年   430篇
  2013年   646篇
  2012年   713篇
  2011年   720篇
  2010年   483篇
  2009年   544篇
  2008年   750篇
  2007年   742篇
  2006年   780篇
  2005年   681篇
  2004年   675篇
  2003年   656篇
  2002年   686篇
  2001年   642篇
  2000年   655篇
  1999年   592篇
  1998年   327篇
  1997年   347篇
  1996年   349篇
  1995年   250篇
  1994年   186篇
  1993年   229篇
  1992年   388篇
  1991年   353篇
  1990年   375篇
  1989年   353篇
  1988年   364篇
  1987年   333篇
  1986年   348篇
  1985年   303篇
  1984年   223篇
  1983年   187篇
  1979年   172篇
  1978年   169篇
  1977年   146篇
  1976年   126篇
  1975年   162篇
  1974年   186篇
  1973年   136篇
  1972年   139篇
  1971年   141篇
  1970年   122篇
排序方式: 共有10000条查询结果,搜索用时 656 毫秒
1.
Introduction: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype associated with an increased risk of recurrence and cancer-related death. Unlike hormone receptor-positive or HER2-positive breast cancers, there are limited targeted therapies available to treat TNBC and cytotoxic chemotherapy remains the mainstay of treatment. Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate targeting Trop-2 expressing cells and selectively delivering SN-38, an active metabolite of irinotecan.

Areas covered: This review covers the mechanism of action, safety and efficacy of sacituzumab govitecan in patients with previously treated, metastatic TNBC. Additionally, efficacy data in other epithelial malignancies is included based on a PubMed search for ‘sacituzumab govitecan’ and ‘clinical trial’.

Expert opinion: Sacituzumab govitecan has promising anti-cancer activity in patients with metastatic TNBC previously treated with at least two prior lines of systemic therapy based on a single arm Phase I/II clinical trial. A confirmatory Phase III randomized clinical trial is ongoing. Sacituzumab govitecan has a manageable side effect profile, with the most common adverse events being nausea, neutropenia, and diarrhea. The activity of sacituzumab govitecan likely extends beyond TNBC with promising early efficacy data in many other epithelial cancers, including hormone receptor-positive breast cancer.  相似文献   

2.
3.
4.
5.
6.
7.
8.
9.
Objectives Compare the effect of high doses of inhaled corticosteroids on bone loss in subjects with moderate to severe asthma or mild asthma, and examine the influence of dietary intake on bone metabolism. Design A survey on the effects of corticotherapy and nutrition on bone density was conducted in 74 subjects currently being treated for asthma in the asthma clinic of Hospital Laval (Sainte-Foy, Quebec, Canada). Fifty-eight subjects completed the study (attrition RATE=15%).

Main outcome measures In all subjects expiratory volumes were determined and urinary analysis was conducted for hydroxyproline, calcium, phosphorus, and cortisol levels. Osteocalcin, calcium, phosphorus, cortisol, alkaline phosphatase, and γ-glutamyltransferase levels were measured in blood samples. Bone density of the lumbar spine was determined by means of dual-energy x-ray absorptiometry. Nutrition evaluation was based on a 3-day food diary analyzed using progiciel Nutri 91. The nutritional parameters examined were calcium; phosphorus; magnesium; zinc; vitamins A, C, and D; protein; total fiber; oxalates; energy; caffeine; and alcohol in relation to bone density.

Subjects Thirty-one patients with moderate to severe asthma who had been taking more than 1,000 μg beclomethasone per day or the equivalent for more than 2 years and 27 patients with mild asthma who were taking less than 500 μg beclomethasone per day or the equivalent.

Statistical analyses performed Four factor analysis of variance with hierarchized interactions of four levels, Duncan's test, Pearson correlation coefficients.

Results Blood levels of osteocalcin and protein intake were lower in patients with moderate to severe asthma than in those with mild asthma (P<.05). Significant correlations (P<.02) were observed between bone density and calcium intake (r=.40), phosphorus intake (r=.35), protein intake (r=.30), and serum alkaline phosphatase level (r=−.30). Bone density was not significantly different between the two groups of patients with asthma.

Applications A follow-up of patients with asthma who are taking inhaled corticosteroids is needed to assess bone density, osteocalcin levels, and dietary intakes of calcium. Verify if osteocalcin level decreases over time in patients with moderate to severe asthma, monitor possible modifications in bone density, and verify if the correlation between dietary calcium and bone density is maintained. J Am Diet Assoc. 1997;97:1401–1406.  相似文献   

10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号